Search

COLUMBUS, Miss. -- Gen. Richard A. Cody, Vice Chief of Staff of the Army, and Joe RedCloud, a chief of the Oglala Sioux Tribe, Lakota Nation, accepted the Army's first [...]

The Army fielded its 200th One-System Remote Video Terminal (OSRVT) to Iraq and Afghanistan last month. Soldiers using an OSRVT can display the sensor feed from any of the Army's [...]

La leishmaniose cutanée (LC) est endémique en Guyane avec 200 à 300 cas/an, sporadique mais concentrée sur la saison des pluies. Les épidémies sont rares et peu investiguées. Un signal épidémique a été émis le 15/03/2020 avec 15 cas suspects de leishmaniose cutanée appartenant au 3eRégiment étranger d’infanterie (REI) et 9eRégiment d’infanterie marine (RIMA), et ayant participé à un stage d’entraînement en forêt équatoriale (CEFE). Une investigation épidémique était alors réalisée.

Background:The purpose of this study was to evaluate the efficacy of corticosteroid injection and determine the duration of symptom-free period after treatment with a single ultrasound-guided injection for a painful Morton's neuroma. Materials and Methods:From May 2002 to November 2003, 35 consecutive patients (7 males, 28 females) (mean age, 54; age range, 29 to 77 years) underwent a single ultrasound guided corticosteroid injection. Thirty-nine injections were performed as 4 patients had bilateral Morton's neuromas. The injection of 1.0 cc Celestone Chronodose (5.7 mg/ml) with 0.5 cc of 1% lidocaine was performed into the symptomatic intermetatarsal web-space. The efficacy of the injection was determined by the Johnson grading scale, and modified lower extremity functional scale. Results:On the Johnson scale, 15 of 39 (38%) neuromas showed complete satisfaction 9 months after treatment and 11 of 39 (28%) were satisfied with minor reservations. A total of 26 of 39 (66%) neuromas had a positive outcome 9 months after the injection. On the functional daily activity (FDA) scale, 20 of 39 (51%) neuromas showed no difficulty and 4 of 39 (10%) indicated minor difficulties, which was considered a positive outcome 9 months after injection. Complete pain relief was achieved in 11 of 39 (28%) neuromas 9 months after treatment. Twelve of 39 (31%) neuromas did not respond to conservative treatment and required surgery. The results of treatment suggested improvement in efficacy if injection was used early. The size of the lesion measured on ultrasound showed no correlation with pain relief after injection. Conclusion:A single corticosteroid injection can offer short-term pain relief in the conservative management of Morton's neuroma.

A focus group comprised of persons who use power wheelchairs and professionals working in the field were asked to participate in a brainstorming session to determine priorities for the development and application of power mobility input devices and control concepts. The group consensus was that durability and reliability are the most important criteria. Essentially, the expectation is that a power wheelchair must work everyday in the way a person needs it and wants it. At the same time, there is a desire to enhance and advance the features of input devices and control systems. Many would say these changes constitute designing “smarter” power wheelchairs, such as systems that can independently detect obstacles and can provide users with more feedback. This paper presents the rationale behind forming this focus group and details of the results of a brainstorming session where ideas were generated and prioritized. The five most important issues as determined by the group are discussed in depth.